ANVS (Annovis Bio Inc) רווח למניה בשנים עשר החודשים האחרונים

This price chart on the GURU.Markets platform demonstrates that Annovis Bio, Inc. (ANVS) has an EPS (TTM) of -14.90, illustrating the price action of the biotech firm developing buntiapine for the treatment of dementia. Annovis Bio, Inc. (ANVS) possesses significant pricing power due to the uniqueness of its formulas. Operational activities rely on external researchers, while patents remain in-house. The asset's value depends on scientific discoveries rather than economic cycles.
Annovis Bio, Inc. - פילוחים אנליטיים ומדדי מפתח (ANVS)

This indicator reflects the rate of change in net earnings per share over a rolling year, calculating the difference between current and previous EPS values to assess capital efficiency. By analyzing the YoY percentage growth of earnings per share over 12 months, an investor can identify the margin volatility of Annovis Bio, Inc. (ANVS), which is critically dependent on the patent status of buntanetap and clinical trial outcomes.